<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VALSARTAN AND HYDROCHLOROTHIAZIDE- valsartan and hydrochlorothiazideÂ tablet, film coatedÂ </strong><br>Proficient Rx LP<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to useÂ valsartan and hydrochlorothiazide tablets USP safely and effectively. See full prescribing information for valsartan and hydrochlorothiazide tablets USP.<br><br>VALSARTAN and HYDROCHLOROTHIAZIDE Tablets, USP for oral use<br>Initial U.S. Approval: 1998<br>
</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: FETAL TOXICITY</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">When pregnancy is detected, discontinue valsartan and hydrochlorothiazide tablets USP as soon as possible. (<a href="#s5p1">5.1</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. (<a href="#s5p1">5.1</a>)</span></dd>
</dl>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: FETAL TOXICITY</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">When pregnancy is detected, discontinue valsartan and hydrochlorothiazide tablets USP as soon as possible. (<a href="#s5p1">5.1</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. (<a href="#s5p1">5.1</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Valsartan and hydrochlorothiazide tablets, USP are the combination tablets of valsartan, an angiotensin II receptor blocker (ARB) and hydrochlorothiazide (HCTZ), a diuretic. </p>
<p class="Highlighta">Valsartan and hydrochlorothiazide tablets, USP are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, to lower blood pressure: </p>
<dl>
<dt>1.</dt>
<dd>In patients not adequately controlled with monotherapy (<a href="#s1">1</a>) </dd>
<dt>2.</dt>
<dd>As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals (<a href="#s1">1</a>)</dd>
</dl>
<p class="Highlighta">Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>. </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Dose once daily. Titrate as needed to a maximum dose of 320/25mg  (<a href="#s2">2</a>)<br>
</dd>
<dt>â€¢</dt>
<dd>May be used as add-on/switch therapy for patients not adequately controlled on any of the components (valsartan or HCTZ)Â (<a href="#s2">2</a>)<br>
</dd>
<dt>â€¢</dt>
<dd>May be substituted for titrated components (<a href="#s2p3">2.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets (valsartan/HCTZ mg): 80/12.5, 160/12.5, 160/25, 320/12.5, 320/25 (<a href="#s3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span>; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any sulfonamide-derived drugs or any component; Do not coadminister aliskiren with valsartan and hydrochlorothiazide tablets in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (<a href="#s4">4</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>: Correct <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> prior to initiation (<a href="#s5p2">5.2</a>)<br>
</dd>
<dt>â€¢</dt>
<dd>Observe for signs of fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> (<a href="#s5p9">5.9</a>)<br>
</dd>
<dt>â€¢</dt>
<dd>Monitor renal function and potassium in susceptible patients (<a href="#s5p3">5.3, </a><a href="#s5p7">5.7</a>) <br>
</dd>
<dt>â€¢</dt>
<dd>Exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> (<a href="#s5p5">5.5</a>)<br>
</dd>
<dt>â€¢</dt>
<dd>Acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> (<a href="#s5p8">5.8</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common reasons for discontinuation of therapy with valsartan and hydrochlorothiazide tablets were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. The only adverse experience that occurred in â‰¥2% of patients treated with valsartan and hydrochlorothiazide tablets and at a higher incidence than placebo was <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> (2.4% vs. 1.9%).Â (<a href="#s6p1">6.1</a>) </p>
<p class="Highlighta"><br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (<a href="#s7">7</a>)<br>
</dd>
<dt>â€¢</dt>
<dd>Cholestyramine and colestipol: Reduced absorption of thiazides (<a href="#_01f312b1-8542-f3c5-bc38-92634e70f905">12.3</a>)<br>
</dd>
<dt>â€¢</dt>
<dd>Lithium: Increased risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Monitor serum lithium concentrations during concurrent use. (<a href="#s7">7</a>)<br>
</dd>
<dt>â€¢</dt>
<dd>Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): May increase risk of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Can reduce diuretic, natriuretic and antihypertensive effects of diuretics. (<a href="#s7">7</a>)</dd>
<dt>â€¢</dt>
<dd>Dual inhibition of the renin-angiotensin system: Increased risk of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (<a href="#s7">7</a>)<br>
</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta"><span class="Bold">Nursing Mothers: </span>Nursing or drug should be discontinued (<a href="#s8p3">8.3</a>)  </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 9/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: FETAL TOXICITY</a></h1>
<h1><a href="#section-1" class="toc">1 Â INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2Â Â DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1Â General Considerations</a></h2>
<h2><a href="#section-2.2" class="toc">2.2Â Add-On Therapy</a></h2>
<h2><a href="#section-2.3" class="toc">2.3Â Replacement Therapy</a></h2>
<h2><a href="#section-2.4" class="toc">2.4Â Initial Therapy</a></h2>
<h2><a href="#section-2.5" class="toc">2.5Â Use with Other Antihypertensive Drugs</a></h2>
<h1><a href="#section-3" class="toc">3 Â DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 Â CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Fetal Toxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> in Volume- and/or Salt-Depleted Patients</a></h2>
<h2><a href="#section-5.3" class="toc">5.3Â <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic Lupus Erythematosus</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Lithium Interaction</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Potassium Abnormalities</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Metabolic Disturbances</a></h2>
<h1><a href="#section-6" class="toc">6 Â ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 Â DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 Â USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10Â Â OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11Â Â DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12Â Â CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13Â Â NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.3Â Developmental Toxicity StudiesÂ </a></h2>
<h1><a href="#section-13" class="toc">14Â Â CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Initial TherapyÂ -Â <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h1><a href="#section-14" class="toc">16Â Â HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="_662018cc-3767-3fb4-c01c-d75556bbac4f"></a><a name="section-1"></a><p></p>
<h1>WARNING: FETAL TOXICITY</h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">When pregnancy is detected, discontinue valsartan and hydrochlorothiazide tablets USP as soon as possible. (<a href="#s5p1">5.1</a>) </span></dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. (<a href="#s5p1">5.1</a>)</span>Â  </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 Â INDICATIONS AND USAGE</h1>
<p class="First">Valsartan and hydrochlorothiazide tablets, USP are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with valsartan and hydrochlorothiazide tablets.</p>
<p>Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Programâ€™s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).</p>
<p>Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, but reductions in <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and cardiovascular mortality have also been seen regularly.</p>
<p>Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (for example, patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.</p>
<p>Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or diabetic kidney disease). These considerations may guide selection of therapy.</p>
<p><span class="Bold">Add-On Therapy </span></p>
<p>Valsartan and hydrochlorothiazide tablets, USP may be used in patients whose blood pressure is not adequately controlled on monotherapy.</p>
<p><span class="Bold">Replacement Therapy </span></p>
<p>Valsartan and hydrochlorothiazide tablets, USP may be substituted for the titrated components.</p>
<p><span class="Bold">Initial Therapy </span></p>
<p>Valsartan and hydrochlorothiazide tablets, USP may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals.</p>
<p>The choice of valsartan and hydrochlorothiazide tablets, USP as initial therapy for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> should be based on an assessment of potential benefits and risks.</p>
<p>Patients with stage 2 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> are at a relatively high risk for cardiovascular events (such as <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>), <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patientâ€™s risk.</p>
<p>Data from the high dose multifactorial trial <span class="Italics"> [see Clinical Studies (<a href="#_050434b6-ae92-0317-47b5-7af08eb657aa">14.1</a>)] </span> provides estimates of the probability of reaching a target blood pressure with valsartan and hydrochlorothiazide tablets compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with valsartan and hydrochlorothiazide tablets 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures.</p>
<table width="100%">
<col width="55%">
<col width="45%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule"><p class="First"><br><a name="id941"></a><img alt="graph-1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6b6ad6c8-22f8-456b-bc54-a02fb6cbea8c&amp;name=graph-1.jpg"><span class="Bold">Figure 1: Probability of Achieving Systolic Blood Pressure &lt;140 mmHg at Week 8</span></p></td>
<td class="Toprule"><p class="First">Â Â <br><a name="id948"></a><img alt="graph-2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6b6ad6c8-22f8-456b-bc54-a02fb6cbea8c&amp;name=graph-2.jpg"><span class="Bold">Figure 2: Probability of Achieving Diastolic Blood PressureÂ &lt;90 mmHg at Week 8</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><br><a name="id958"></a><img alt="graph-3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6b6ad6c8-22f8-456b-bc54-a02fb6cbea8c&amp;name=graph-3.jpg"><span class="Bold">Figure 3: Probability of Achieving Systolic Blood Pressure &lt;130 mmHg at Week 8</span><br></p></td>
<td class="Botrule"><p class="First"><br><a name="id966"></a><img alt="graph-4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6b6ad6c8-22f8-456b-bc54-a02fb6cbea8c&amp;name=graph-4.jpg"><span class="Bold">Figure 4: Probability of Achieving Diastolic Blood PressureÂ &lt;80 mmHg at Week 8</span></p></td>
</tr>
</tbody>
</table>
<p>For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of &lt;140 mmHg (systolic) and 60% likelihood of achieving &lt;90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on valsartan and hydrochlorothiazide tablets rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2Â Â DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p1"></a><a name="section-2.1"></a><p></p>
<h2>2.1Â General Considerations</h2>
<p class="First">The usual starting dose is valsartan and hydrochlorothiazide tablets 160/12.5 mg once daily. The dosage can be increased after 1 to 2 weeks of therapy to a maximum of one 320/25 tablet once daily as needed to control blood pressure <span class="Italics">[see Clinical Studies (<a href="#_b63f0241-f1e9-e4f1-cc83-83dcc159d8d0">14.2</a>)]</span>. Maximum antihypertensive effects are attained within 2 to 4 weeks after a change in dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p2"></a><a name="section-2.2"></a><p></p>
<h2>2.2Â Add-On Therapy</h2>
<p class="First">A patient whose blood pressure is not adequately controlled with valsartan (or another ARB) alone or hydrochlorothiazide alone may be switched to combination therapy with valsartan and hydrochlorothiazide tablets. </p>
<p>A patient who experiences dose-limiting adverse reactions on either component alone may be switched to valsartan and hydrochlorothiazide tablets  containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. The clinical response to valsartan and hydrochlorothiazide tablets should be subsequently evaluated and if blood pressure remains uncontrolled after 3 to 4 weeks of therapy, the dose may be titrated up to a maximum ofÂ 320/25 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p3"></a><a name="section-2.3"></a><p></p>
<h2>2.3Â Replacement Therapy</h2>
<p class="First">Valsartan and hydrochlorothiazide tablets may be substituted for the titrated components.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p4"></a><a name="section-2.4"></a><p></p>
<h2>2.4Â Initial Therapy</h2>
<p class="First">Valsartan and hydrochlorothiazide tablets are not recommended as initial therapy in patients with intravascular <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> <span class="Italics">[see Warnings and Precautions (<a href="#s5p2">5.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p5"></a><a name="section-2.5"></a><p></p>
<h2>2.5Â Use with Other Antihypertensive Drugs</h2>
<p class="First">Valsartan and hydrochlorothiazide tablets may be administered with other antihypertensive agents.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3 Â DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">80/12.5 mg tablets are orange, modified capsule shaped, film-coated tablets, engraved â€œAPOâ€? on one side and â€œ80/12.5â€? on the other side.</p>
<p>160/12.5 mg tablets are dark red, modified capsule shaped, film-coated tablets, engraved â€œAPOâ€? on one side and â€œ160/12.5â€? on the other side. </p>
<p>160/25 mg tablets are brown, modified capsule shaped, film-coated tablets, engraved â€œAPOâ€? on one side and â€œ160/25â€? on the other side.</p>
<p>320/12.5 mg tablets are pink, oval, film-coated tablets, engraved â€œAPOâ€? on one side and â€œ320/12.5â€? on the other side.</p>
<p>320/25 mg tablets are yellow, oval, film-coated tablets, engraved â€œAPOâ€? on one side and â€œ320/25â€? on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>4 Â CONTRAINDICATIONS</h1>
<p class="First">Valsartan and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product.</p>
<p>Because of the hydrochlorothiazide component, this product is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other sulfonamide-derived drugs.</p>
<p style="border-left:1px solid;">Do not co<span class="XmChange">administer</span> aliskiren with valsartan and hydrochlorothiazide tablets in patients with <span class="XmChange"><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> </span><span class="Italics">[see Drug Interactions (<a href="#s7">7</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Fetal Toxicity</h2>
<p class="First"><span class="Bold"><span class="Italics">Pregnancy Category D</span></span></p>
<p>Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. When pregnancy is detected, discontinue valsartan and hydrochlorothiazide tablets as soon as possible [see Use in Specific Populations (<a href="#s8p1">8.1</a>)].</p>
<p>Intrauterine exposure to thiazide diuretics is associated with fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions that have occurred in adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> in Volume- and/or Salt-Depleted Patients</h2>
<p class="First">Excessive reduction of blood pressure was rarely seen (0.7%) in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncomplicated hypertension</span> treated with valsartan and hydrochlorothiazide tablets in controlled trials. In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occur. This condition should be corrected prior to administration of valsartan and hydrochlorothiazide tablets, or the treatment should start under close medical supervision.</p>
<p>If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p3"></a><a name="section-5.3"></a><p></p>
<h2>5.3Â <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">Changes in renal function including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> can be caused by drugs that inhibit the renin-angiotensin system and by diuretics. Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">renal artery stenosis</span>, <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span>, severe <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, or <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>) may be at particular risk of developing <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> on valsartan and hydrochlorothiazide tablets. Monitor renal function periodically in these patients. </p>
<p>Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on valsartan and hydrochlorothiazide tablets <span class="Italics">[see Drug Interactions (<a href="#s7">7</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></h2>
<p class="First"><span class="Bold"><span class="Italics">Hydrochlorothiazide</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> to hydrochlorothiazide may occur in patients with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, but are more likely in patients with such a history.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic Lupus Erythematosus</span></h2>
<p class="First"><span class="Bold"><span class="Italics">Hydrochlorothiazide  </span></span></p>
<p>Thiazide diuretics have been reported to cause exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Lithium Interaction</h2>
<p class="First">Increases in serum lithium concentrations and <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> have been reported with concomitant use of valsartan or thiazide diuretics. Monitor lithium levels in patients receiving valsartan and hydrochlorothiazide tabletsÂ and lithium <span class="Italics">[see Drug Interactions (<a href="#s7">7</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Potassium Abnormalities</h2>
<p class="First"><span class="Bold"><span class="Italics">Valsartan â€“ Hydrochlorothiazide </span></span></p>
<p>In the controlled trials of various doses of valsartan and hydrochlorothiazide tablets the incidence of hypertensive patients who developed <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (serum potassium &lt;3.5Â mEq/L) was 3.0%; the incidence of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (serum potassium &gt;5.7Â mEq/L) was 0.4%.</p>
<p>Hydrochlorothiazide can cause <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>. <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> can result in <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> which appears difficult to treat despite potassium repletion. Drugs that inhibit the renin-angiotensin system can cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. Monitor serum electrolytes periodically. </p>
<p>If <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> is accompanied by clinical signs (e.g. <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span>, or ECG alterations), valsartan and hydrochlorothiazide tablets should be discontinued. Correction of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and any coexisting <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> is recommended prior to the initiation of thiazides.</p>
<p>Some patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> have developed increases in potassium with valsartan therapy. These effects are usually minor and transient, and they are more likely to occur in patients with pre-existing <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Dosage reduction and/or discontinuation of the diuretic and/or valsartan may be required   [see Adverse Reactions (<a href="#s6p1">6.1</a>)]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First">Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span> and acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Symptoms include acute onset of decreased visual acuity or <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> can lead to permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> may include a history of sulfonamide or <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">penicillin allergy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Metabolic Disturbances</h2>
<p class="First"><span class="Bold"><span class="Italics">Hydrochlorothiazide</span></span></p>
<p>Hydrochlorothiazide may alter glucose tolerance and raise serum levels of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides.</p>
<p>Hydrochlorothiazide may raise the serum uric acid level due to reduced clearance of uric acid and may cause or exacerbate <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> and precipitate <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> in susceptible patients.</p>
<p>Hydrochlorothiazide decreases urinary calcium excretion and may cause elevations of serum calcium. Monitor calcium levels in patients with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> receiving valsartan and hydrochlorothiazide tablets. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>6 Â ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s6p1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reactions rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </span></span></p>
<p>Valsartan and hydrochlorothiazide tablets have been evaluated for safety in more than 5,700 patients, including over 990 treated for over 6 months, and over 370 for over 1 year. Adverse experiences have generally been mild and transient in nature and have only infrequently required discontinuation of therapy. The overall incidence of adverse reactions with valsartan and hydrochlorothiazide tablets was comparable to placebo.</p>
<p>The overall frequency of adverse reactions was neither dose-related nor related to gender, age, or race. In controlled clinical trials, discontinuation of therapy due to side effects was required in 2.3% of valsartan-hydrochlorothiazide patients and 3.1% of placebo patients. The most common reasons for discontinuation of therapy with valsartan and hydrochlorothiazide tablets were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p>The only adverseÂ reaction that occurred in controlled clinical trials in at least 2% of patients treated with valsartan and hydrochlorothiazide tablets and at a higher incidence in valsartan-hydrochlorothiazide (n=4372) than placebo (n=262) patients was <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> (2.4% vs. 1.9%).</p>
<p>Dose-related orthostatic effects were seen in fewer than 1% of patients. In individual trials, a dose-related increase in the incidence of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> was observed in patients treated with valsartan and hydrochlorothiazide tablets.</p>
<p>Other adverse reactions that have been reported with valsartan-hydrochlorothiazide (&gt;0.2% of valsartan-hydrochlorothiazide patients in controlled clinical trials) without regard to causality, are listed below:</p>
<p><span class="Bold"><span class="Italics">Cardiovascular: </span></span><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p><span class="Bold"><span class="Italics">Ear and Labyrinth: </span></span><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span> and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Bold"><span class="Italics">Gastrointestinal: </span></span><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Bold"><span class="Italics">General and Administration Site Conditions: </span></span><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span></p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>: </span></span><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis acute</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span> and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></p>
<p><span class="Bold"><span class="Italics">Investigations: </span></span>Blood urea increased</p>
<p><span class="Bold"><span class="Italics">Musculoskeletal: </span></span><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span></p>
<p><span class="Bold"><span class="Italics">Nervous System: </span></span><span class="product-label-link" type="condition" conceptid="4250121" conceptname="Dizziness on standing up">Dizziness postural</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span></p>
<p><span class="Bold"><span class="Italics">Psychiatric: </span></span><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span></p>
<p><span class="Bold"><span class="Italics">Renal and Urinary: </span></span><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Pollakiuria</span></p>
<p><span class="Bold"><span class="Italics">Reproductive System: </span></span><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile dysfunction</span></p>
<p><span class="Bold"><span class="Italics">Respiratory, Thoracic and Mediastinal: </span></span><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4220211" conceptname="Congestion of nasal sinus">sinus congestion</span></p>
<p><span class="Bold"><span class="Italics">Skin and Subcutaneous Tissue: </span></span><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p><span class="Bold"><span class="Italics">Vascular: </span></span><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p>
<p>Other reported reactions seen less frequently in clinical trials included <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, sunburn, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, and <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>.</p>
<p><span class="Bold"><span class="Italics">Initial Therapy - <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></span></p>
<p>In a clinical study in patients with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic blood pressure â‰¥110 mmHg and systolic blood pressure â‰¥140 mmHg), the overall pattern of adverse reactions reported through six weeks of follow-up was similar in patients treated with valsartan and hydrochlorothiazide tablets as initial therapy and in patients treated with valsartan as initial therapy. Comparing the groups treated with valsartan and hydrochlorothiazide tablets (force-titrated to 320/25 mg) and valsartan (force-titrated to 320 mg), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> was observed in 6% and 2% of patients, respectively. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> was observed in 1% of those patients receiving valsartan and hydrochlorothiazide tablets and 0% of patients receiving valsartan. There were no reported cases of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> in either treatment group. Laboratory changes with valsartan and hydrochlorothiazide tablets as initial therapy in patients with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> were similar to those reported with valsartan and hydrochlorothiazide tablets in patients with less severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> <span class="Italics">[see Clinical Studies (<a href="#_b63f0241-f1e9-e4f1-cc83-83dcc159d8d0">14.2</a>) and Drug Interactions (<a href="#s7">7</a>)].</span></p>
<p><span class="Italics">Valsartan</span></p>
<p>In trials in which valsartan was compared to an ACE inhibitor with or without placebo, the incidence of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">dry cough</span> was significantly greater in the ACE inhibitor group (7.9%) than in the groups who received valsartan (2.6%) or placebo (1.5%). In a 129-patient trial limited to patients who had had <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">dry cough</span> when they had previously received ACE inhibitors, the incidences of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> in patients who received valsartan, hydrochlorothiazide, or lisinopril were 20%, 19%, 69% respectively (p &lt;0.001).</p>
<p>Other reported reactions seen less frequently in clinical trials included <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p><span class="Italics">Hydrochlorothiazide</span></p>
<p>Other adverse reactions not listed above that have been reported with hydrochlorothiazide, without regard to causality, are listed below:</p>
<p><span class="Bold"><span class="Italics">Body As A Whole: </span></span><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></p>
<p><span class="Bold"><span class="Italics">Digestive: </span></span><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, cramping, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span></p>
<p><span class="Bold"><span class="Italics">Hematologic: </span></span><span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: </span></span><span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span> (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> and <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span></p>
<p><span class="Bold"><span class="Italics">Metabolic: </span></span><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span></p>
<p><span class="Bold"><span class="Italics">Musculoskeletal: </span></span><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span></p>
<p><span class="Bold"><span class="Italics">Nervous System/Psychiatric: </span></span><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></p>
<p><span class="Bold"><span class="Italics">Renal: </span></span><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, renal dysfunction, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span></p>
<p><span class="Bold"><span class="Italics">Skin: </span></span><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span></p>
<p><span class="Bold"><span class="Italics">Special Senses: </span></span>transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span></p>
<p><span class="Bold">Clinical Laboratory Test Findings</span></p>
<p>In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of valsartan and hydrochlorothiazide tablets.</p>
<p><span class="Bold"><span class="Italics">Creatinine/Blood Urea Nitrogen (BUN): </span></span>Minor elevations in creatinine and BUN occurred in 2% and 15% respectively, of patients taking valsartan and hydrochlorothiazide tablets and 0.4% and 6% respectively, given placebo in controlled clinical trials.</p>
<p><span class="Bold"><span class="Italics">Hemoglobin and Hematocrit: </span></span>Greater than 20% decreases in hemoglobin and hematocrit were observed in less than 0.1% of valsartan and hydrochlorothiazide tablets patients, compared with 0% in placebo-treated patients.</p>
<p><span class="Bold"><span class="Italics">Liver Function Tests: </span></span>Occasional elevations (greater than 150%) of liver chemistries occurred in valsartan and hydrochlorothiazide-treated patients.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>: </span></span><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> was observed in 0.1% of patients treated with valsartan and hydrochlorothiazide tablets and 0.4% of patients treated with placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6p2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following additional adverse reactions have been reported in valsartan or valsartan/hydrochlorothiazideÂ postmarketing experience. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></span></p>
<p>There are rare reports of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>. Some of these patients previously experienced <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> with other drugs including ACE inhibitors. Valsartan and hydrochlorothiazide tablets should not be re-administered to patients who have had <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p><span class="Bold"><span class="Italics">Digestive: </span></span>Elevated liver enzymes and very rare reports of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span></p>
<p><span class="Bold"><span class="Italics">Renal: </span></span><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span></p>
<p><span class="Bold"><span class="Italics">Clinical Laboratory Tests: </span></span><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></p>
<p><span class="Bold"><span class="Italics">Dermatologic: </span></span><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">bullous dermatitis</span></p>
<p><span class="Bold"><span class="Italics">Vascular:</span></span> <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span></p>
<p><span class="Bold"><span class="Italics">Nervous System: </span></span><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></p>
<p>Rare cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients receiving angiotensin II receptor blockers.</p>
<p><span class="Bold"><span class="Italics">Hydrochlorothiazide </span></span></p>
<p>The following additional adverse reactions have been reported in post-marketing experience with hydrochlorothiazide:</p>
<p><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disorder</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">bone marrow failure</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">worsening of diabetes</span> control, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, blood <span class="product-label-link" type="condition" conceptid="4051221" conceptname="Increased lipid">lipids increased</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, and <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span>. </p>
<p>Pathological changes in the parathyroid gland of patients with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> and <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> have been observed in a few patients on prolonged thiazide therapy. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs, further diagnostic evaluation is necessary.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s7"></a><a name="section-7"></a><p></p>
<h1>7 Â DRUG INTERACTIONS</h1>
<p class="First"><span class="Bold">Valsartan-Hydrochlorothiazide </span></p>
<p><span class="Bold"><span class="Italics">Lithium</span></span></p>
<p>Increases in serum lithium concentrations and <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> have been reported during concomitant administration of lithium with angiotensin II receptor antagonists or thiazides. Monitor lithium levels in patients takingÂ valsartan and hydrochlorothiazide tablets.</p>
<p><span class="Bold">Valsartan</span></p>
<p>No clinically significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were observed when valsartan was coadministered with amlodipine, atenolol, cimetidine, digoxin, furosemide, glyburide, hydrochlorothiazide,Â or indomethacin. The valsartan-atenolol combination was more antihypertensive than either component, but it did not lower the heart rate more than atenolol alone.</p>
<p>Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin.</p>
<p><span class="Bold"><span class="Italics">CYP Â  450 Interactions </span></span></p>
<p><span class="Italics">In vitro </span>metabolism studies indicate that CYP 450 mediated drug interactions between valsartan and co-administered drugs are unlikely because of the low extent of metabolism <span class="Italics">[see Clinical Pharmacology (<a href="#_01f312b1-8542-f3c5-bc38-92634e70f905">12.3</a>)]</span>.</p>
<p><span class="Bold"><span class="Italics">Transporters </span></span></p>
<p>The results from an <span class="Italics">in vitro</span> study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and the hepatic efflux transporter MRP2. Coadministration of inhibitors of the uptake transporter (rifampin, cyclosporine) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan.</p>
<p><span class="Bold"><span class="Italics">Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)</span></span></p>
<p>In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including valsartan, may result in deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. These effects are usually reversible. Monitor renal function periodically in patients receiving valsartan and NSAID therapy. </p>
<p>The antihypertensive effect of angiotensin II receptor antagonists, including valsartan may be attenuated by NSAIDs including selective COX-2 inhibitors.</p>
<p><span class="Bold"><span class="Italics">Potassium </span></span></p>
<p>Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium sparing diuretics (e.g. spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients to increases in serum creatinine. If co-medication is considered necessary, monitoring of serum potassium is advisable.</p>
<p><span class="Bold"><span class="Italics">Dual Blockade of the Renin-Angiotensin System (RAS) </span></span></p>
<p>Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, and changes in renal function (including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>) compared to monotherapy. Closely monitor blood pressure, renal function, and electrolytes in patients on valsartan and hydrochlorothiazide tablets and other agents that affect the RAS.Â </p>
<p>Do not coadminister aliskiren with valsartan and hydrochlorothiazide tablets in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Avoid use of aliskiren with valsartan and hydrochlorothiazide tablets in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR &lt;60 ml/min).</p>
<p><span class="Bold">Hydrochlorothiazide</span></p>
<p>When administered concurrently, the following drugs may interact with thiazide diuretics:</p>
<p><span class="Bold"><span class="Italics">Antidiabetic Drugs</span> (oral agents and insulin) </span></p>
<p>Dosage adjustment of the antidiabetic drug may be required.</p>
<p><span class="Bold"><span class="Italics">Nonsteroidal Anti-inflammatory Drugs</span>Â (NSAIDs and COX-2 selective inhibitors) </span></p>
<p>When valsartan and hydrochlorothiazide tablets and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.</p>
<p><span class="Bold"><span class="Italics">Carbamazepine </span></span></p>
<p>May lead to symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<p><span class="Bold"><span class="Italics">Ion exchange resins </span></span></p>
<p><span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Staggering</span> the dosage of hydrochlorothiazide and ion exchange resins (e.g., cholestyramine, colestipol) such that hydrochlorothiazide is administered at least 4 hours before or 4 to 6 hours after the administration of resins would potentially minimize the interaction <span class="Italics">[see Clinical Pharmacology (<a href="#_01f312b1-8542-f3c5-bc38-92634e70f905">12.3</a>)].</span></p>
<p><span class="Bold"><span class="Italics">Cyclosporine </span></span></p>
<p>Concomitant treatment with cyclosporine may increase the risk of <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> and <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>-type complications.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s8"></a><a name="section-8"></a><p></p>
<h1>8 Â USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s8p1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold"><span class="Italics">Pregnancy Category D </span></span></p>
<p>Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. When pregnancy is detected, discontinue valsartan and hydrochlorothiazide tablets as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> during pregnancy is important to optimize outcomes for both mother and fetus.</p>
<p>In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> is observed, discontinue valsartan and hydrochlorothiazide tablets, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of <span class="Italics">in utero</span> exposure to valsartan and hydrochlorothiazide tablets for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> <span class="Italics">[see Use in Specific Populations (<a href="#s8p4">8.4</a>)]</span>. </p>
<p><span class="Bold"><span class="Italics">Hydrochlorothiazide </span></span></p>
<p>Thiazides can cross the placenta, and concentrations reached in the umbilical vein approach those in the maternal plasma. Hydrochlorothiazide, like other diuretics, can cause placental <span class="product-label-link" type="condition" conceptid="4131044" conceptname="Hypoperfusion">hypoperfusion</span>. It accumulates in the amniotic fluid, with reported concentrations up to 19 times higher than in umbilical vein plasma. Use of thiazides during pregnancy is associated with a risk of fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span> or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. Since they do not prevent or alter the course of EPH (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>) <span class="product-label-link" type="condition" conceptid="439393" conceptname="Pre-eclampsia">gestosis</span> (pre-<span class="product-label-link" type="condition" conceptid="443700" conceptname="Eclampsia">eclampsia</span>), these drugs should not be used to treat <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in pregnant women. The use of hydrochlorothiazide for other indications (e.g., heart disease) in pregnancy should be avoided.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s8p3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether valsartan is excreted in human milk. Valsartan was excreted into the milk of lactating rats; however, animal breast milk drug levels may not accurately reflect human breast milk levels. Hydrochlorothiazide is excreted in human breast milk. Because many drugs are excreted into human milk and because of the potential for adverse reactions in nursing infants from valsartan and hydrochlorothiazide tablets, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s8p4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of valsartan and hydrochlorothiazide tablets in pediatric patients have not been established.</p>
<p><span class="Bold"><span class="Italics">Neonates with a history of  in utero  exposure to valsartan and hydrochlorothiazide tablets</span></span></p>
<p>If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or substituting for disordered renal function. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s8p5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In the controlled clinical trials of valsartan and hydrochlorothiazide tablets, 764 (17.5%) patients treated with valsartan-hydrochlorothiazide were â‰¥65Â years and 118 (2.7%) were â‰¥75Â years. No overall difference in the efficacy or safety of valsartan-hydrochlorothiazide was observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8p6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Safety and effectiveness of valsartan and hydrochlorothiazide tablets in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl â‰¤ 30 mL/min) have not been established. No dose adjustment is required in patients with mild (CrCl 60 to 90 mL/min) or moderate (CrCl 30 to 60) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8p7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First"><span class="Bold"><span class="Italics">Valsartan</span></span></p>
<p>No dose adjustment is necessary for patients with mild-to-moderate liver disease. No dosing recommendations can be provided for patients with severe liver disease. </p>
<p><span class="Bold"><span class="Italics">Hydrochlorothiazide </span></span></p>
<p>Minor alterations of fluid and electrolyte balance may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> in patients with impaired hepatic function or progressive liver disease.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s10"></a><a name="section-9"></a><p></p>
<h1>10Â Â OVERDOSAGE</h1>
<p class="First"><span class="Bold">Valsartan â€“ Hydrochlorothiazide</span></p>
<p>Limited data are available related to overdosage in humans. The most likely manifestations of overdosage would be <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> could occur from parasympathetic (vagal) stimulation. <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">Depressed level of consciousness</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> have been reported. If symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> should occur, supportive treatment should be instituted.</p>
<p>Valsartan is not removed from the plasma by dialysis.</p>
<p>The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The most common signs and symptoms observed in patients are those caused by <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>) and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> resulting from excessive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. If digitalis has also been administered, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may accentuate <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</p>
<p>In rats and marmosets, single oral doses of valsartan up to 1524 and 762Â mg/kg in combination with hydrochlorothiazide at doses up to 476 and 238Â mg/kg, respectively, were very well tolerated without any treatment-related effects. These no adverse effect doses in rats and marmosets, respectively, represent 46.5 and 23 times the maximum recommended human dose (MRHD) of valsartan and 188 and 113 times the MRHD of hydrochlorothiazide on aÂ mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320Â mg/day valsartan in combination with 25Â mg/day hydrochlorothiazide and a 60-kg patient.)</p>
<p><span class="Bold">Valsartan</span></p>
<p>Valsartan was without grossly observable adverse effects at single oral doses up to 2000Â mg/kg in rats and up to 1000Â mg/kg in marmosets, except for <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in the rat and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in the marmoset at the highest dose (60 and 31 times, respectively, the MRHD on a mg/m<span class="Sup">2</span> basis). (Calculations assume an oral dose of 320Â mg/day and a 60-kg patient.)</p>
<p><span class="Bold">Hydrochlorothiazide</span></p>
<p>The oral LD<span class="Sub">50</span> of hydrochlorothiazide is greater than 10Â g/kg in both mice and rats, which represents 2027 and 4054 times, respectively, the MRHD on aÂ mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 25Â mg/day and a 60-kg patient.)</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s11"></a><a name="section-10"></a><p></p>
<h1>11Â Â DESCRIPTION</h1>
<p class="First">Valsartan and hydrochlorothiazide tablets, USP are a combination of valsartan, an orally active, specific angiotensin II receptor blocker (ARB) acting on the AT<span class="Sub">1</span> receptor subtype, and hydrochlorothiazide, a diuretic.</p>
<p>Valsartan, a nonpeptide molecule, is chemically described as <span class="Italics">N</span>-(1-oxopentyl)-<span class="Italics">N</span>-[[2â€²-(1<span class="Italics">H</span>-tetrazol-5-yl)[1,1â€²-biphenyl]-4-yl]methyl]-L-Valine. Its empirical formula is C<span class="Sub">24</span>H<span class="Sub">29</span>N<span class="Sub">5</span>O<span class="Sub">3</span>, its molecular weight is 435.52, and its structural formula is</p>
<p> Â Â Â Â Â  <a name="id1730"></a><img alt="Valsartan structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6b6ad6c8-22f8-456b-bc54-a02fb6cbea8c&amp;name=Valsartn-structure.jpg"></p>
<p>Valsartan is a white to practically white fine powder. It is soluble in ethanol and methanol and slightly soluble in water.</p>
<p>Hydrochlorothiazide USP is a white, or practically white, practically odorless, crystalline powder. It is slightly soluble in water; freely soluble in sodium hydroxide solution, in <span class="Italics">n</span>-butylamine, and in dimethylformamide; sparingly soluble in methanol; and insoluble in ether, in chloroform, and in dilute mineral acids. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2<span class="Italics">H</span>-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide.</p>
<p>Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C<span class="Sub">7</span>H<span class="Sub">8</span>ClN<span class="Sub">3</span>O<span class="Sub">4</span>S<span class="Sub">2</span>, its molecular weight is 297.73, and its structural formula is</p>
<p><a name="id1742"></a><img alt="hydrochlorothiazide structural formula " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6b6ad6c8-22f8-456b-bc54-a02fb6cbea8c&amp;name=hydrochlorothiazide-structure.jpg">Â </p>
<p>Valsartan and hydrochlorothiazide tablets, USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, USP 80/12.5Â mg, 160/12.5Â mg, 160/25Â mg, 320/12.5Â mg and 320/25Â mg. The inactive ingredients of the tablets are dibasic calcium phosphate dihydrate, powdered cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate (vegetable source), hydroxypropyl methylcellulose, hydroxypropyl cellulose, titanium dioxide, yellow iron oxide (80/12.5 mg, 160/25 mg and 320/25 mg), euroxide red iron oxide (80/12.5 mg, 160/12.5 mg, 160/25 mg and 320/12.5 mg) and black iron oxide (160/25 mg and 320/12.5 mg).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="_5b961bd9-d427-7ec0-159f-0f1a7f18c878"></a><a name="section-11"></a><p></p>
<h1>12Â Â CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="_27761f3c-bf71-5161-0ab5-1ba2f54b9772"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT<span class="Sub">1</span> receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis.</p>
<p>There is also an AT<span class="Sub">2</span> receptor found in many tissues, but AT<span class="Sub">2</span> is not known to be associated with cardiovascular homeostasis. Valsartan has much greater affinity (about 20,000-fold) for the AT<span class="Sub">1</span> receptor than for the AT<span class="Sub">2</span> receptor. The primary metabolite of valsartan is essentially inactive with an affinity for the AT<span class="Sub">1</span> receptor about one 200th that of valsartan itself.</p>
<p>Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE. Because valsartan does not inhibit ACE (kininase II) it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known. Valsartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p>
<p>Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of valsartan on blood pressure.</p>
<p>Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.</p>
<p>The mechanism of the antihypertensive effect of thiazides is unknown.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="_e323921b-207e-62e2-29a3-3d3a3138e986"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Bold"><span class="Italics">Valsartan</span></span></p>
<p>Valsartan inhibits the pressor effect of angiotensin II infusions. An oral dose of 80 mg inhibits the pressor effect by about 80% at peak with approximately 30% inhibition persisting for 24Â hours. No information on the effect of larger doses is available.</p>
<p>Removal of the negative feedback of angiotensin II causes a 2- to 3-fold rise in plasma renin and consequent rise in angiotensin II plasma concentration in hypertensive patients. Minimal decreases in plasma aldosterone were observed after administration of valsartan; very little effect on serum potassium was observed.</p>
<p><span class="Bold"><span class="Italics">Hydrochlorothiazide </span></span></p>
<p>After oral administration of hydrochlorothiazide, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.</p>
<p><span class="Bold"><span class="Italics">Drug Interactions </span></span></p>
<p><span class="Italics">Hydrochlorothiazide</span></p>
<p><span class="Italics">Alcohol, barbiturates, or narcotics: </span>Potentiation of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> may occur.</p>
<p><span class="Italics">Skeletal muscle relaxants: </span>Possible increased responsiveness to muscle relaxants such as curare derivatives.</p>
<p><span class="Italics">Digitalis glycosides: </span>Thiazide-induced <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> may predispose the patient to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="_01f312b1-8542-f3c5-bc38-92634e70f905"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold"><span class="Italics">Valsartan </span></span></p>
<p>Valsartan peak plasma concentration is reached 2 to 4 hours after dosing. Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours. Absolute bioavailability for the capsule formulation is about 25% (range 10% to 35%). Food decreases the exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (C<span class="Sub">max</span>) by about 50%. AUC and C<span class="Sub">max</span> values of valsartan increase approximately linearly with increasing dose over the clinical dosing range. Valsartan does not accumulate appreciably in plasma following repeated administration.</p>
<p><span class="Bold"><span class="Italics">Hydrochlorothiazide </span></span></p>
<p>The estimated absolute bioavailability of hydrochlorothiazide after oral administration is about 70%. Peak plasma hydrochlorothiazide concentrations (C<span class="Sub">max</span>) are reached within 2 to 5 hours after oral administration. There is no clinically significant effect of food on the bioavailability of hydrochlorothiazide. </p>
<p>Hydrochlorothiazide binds to albumin (40 to 70%) and distributes into erythrocytes. Following oral administration, plasma hydrochlorothiazide concentrations decline bi-exponentially, with a mean distribution half-life of about 2 hours and an elimination half-life of about 10 hours. </p>
<p><span class="Bold"><span class="Italics">Valsartan and hydrochlorothiazide tablets </span></span></p>
<p>Valsartan and hydrochlorothiazide tablets may be administered with or without food.</p>
<p><span class="Bold">Distribution</span></p>
<p><span class="Bold"><span class="Italics">Valsartan </span></span></p>
<p>The steady state volume of distribution of valsartan after intravenous administration is small (17Â L), indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (95%), mainly serum albumin.</p>
<p><span class="Bold">Metabolism</span></p>
<p><span class="Bold"><span class="Italics">Valsartan </span></span></p>
<p>The primary metabolite, accounting for about 9% of dose, is valeryl 4-hydroxy valsartan. <span class="Italics">In vitro</span> metabolism studies involving recombinant CYP 450 enzymes indicated that the CYP 2C9 isoenzyme is responsible for the formation of valeryl-4-hydroxy valsartan. Valsartan does not inhibit CYP 450 isozymes at clinically relevant concentrations. CYP 450 mediated drug interaction between valsartan and coadministered drugs are unlikely because of the low extent of metabolism.</p>
<p><span class="Bold"><span class="Italics">Hydrochlorothiazide</span></span></p>
<p>Is not metabolized.</p>
<p><span class="Bold">Excretion</span></p>
<p><span class="Bold"><span class="Italics">Valsartan </span></span></p>
<p>Valsartan, when administered as an oral solution, is primarily recovered in feces (about 83% of dose) and urine (about 13% of dose). The recovery is mainly as unchanged drug, with only about 20% of dose recovered as metabolites.</p>
<p>Following intravenous administration, plasma clearance of valsartan is about 2Â L/h and its renal clearance is 0.62Â L/h (about 30% of total clearance).</p>
<p><span class="Bold"><span class="Italics">Hydrochlorothiazide </span></span></p>
<p>About 70% of an orally administered dose of hydrochlorothiazide is eliminated in the urine as unchanged drug. </p>
<p><span class="Bold">Special Populations</span></p>
<p><span class="Bold"><span class="Italics">Geriatric </span></span></p>
<p>Exposure (measured by AUC) to valsartan is higher by 70% and the half-life is longer by 35% in the elderly than in the young. A limited amount of data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly subjects compared to young healthy volunteers. </p>
<p><span class="Bold"><span class="Italics">Gender </span></span></p>
<p>Pharmacokinetics of valsartan do not differ significantly between males and females.</p>
<p><span class="Bold"><span class="Italics">Race </span></span></p>
<p>Pharmacokinetic differences due to race have not been studied.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span> </span></span></p>
<p>There is no apparent correlation between renal function (measured by creatinine clearance) and exposure (measured by AUC) to valsartan in patients with different degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Valsartan has not been studied in patients with severe impairment of renal function (creatinine clearance &lt;10 mL/min). Valsartan is not removed from the plasma by hemodialysis. </p>
<p>In a study in individuals with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, the mean elimination half-life of hydrochlorothiazide was doubled in individuals with mild/moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (30 &lt; CrCl &lt; 90 mL/min) and tripled in severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (â‰¤ 30 mL/min), compared to individuals with normal renal function (CrCl &gt; 90 mL/min) <span class="Italics">[see Use in Specific Populations (<a href="#s8p6">8.6</a>)].</span></p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span> </span></span></p>
<p> On average, patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> have twice the exposure (measured by AUC values) to valsartan of healthy volunteers (matched by age, sex, and weight) <span class="Italics">[see Use in Specific Populations (<a href="#s8p7">8.7</a>)].</span></p>
<p><span class="Bold">Drug Interactions</span></p>
<p><span class="Bold"><span class="Italics">Hydrochlorothiazide</span></span></p>
<p><span class="Italics">Drugs that alter gastrointestinal motility </span></p>
<p>The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g., atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. Conversely, pro-kinetic drugs may decrease the bioavailability of thiazide diuretics.</p>
<p><span class="Italics">Cholestyramine </span></p>
<p>In a dedicated drug interaction study, administration of cholestyramine 2 hours before hydrochlorothiazide resulted in a 70% reduction in exposure to hydrochlorothiazide. Further, administration of hydrochlorothiazide 2 hours before cholestyramine resulted in 35% reduction in exposure to hydrochlorothiazide. </p>
<p><span class="Italics">Antineoplastic agents (e.g., cyclophosphamide, methotrexate) </span></p>
<p>Concomitant use of thiazide diuretics may reduce renal excretion of cytotoxic agents and enhance their myelosuppressive effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="_47a0b030-987f-ac35-416f-fc337e11fbd2"></a><a name="section-12"></a><p></p>
<h1>13Â Â NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="_076a9cbe-16ad-1172-59e0-32979573d7ee"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Bold"><span class="Italics">Valsartan-Hydrochlorothiazide </span></span></p>
<p>No carcinogenicity, mutagenicity, or fertility studies have been conducted with the combination of valsartan and hydrochlorothiazide. However, these studies have been conducted for valsartan as well as hydrochlorothiazide alone. Based on the preclinical safety and human pharmacokinetic studies, there is no indication of any adverse interaction between valsartan and hydrochlorothiazide.</p>
<p><span class="Bold"><span class="Italics">Valsartan</span></span></p>
<p>There was no evidence of carcinogenicity when valsartan was administered in the diet to mice and rats for up to 2Â years at doses up to 160 and 200Â mg/kg/day, respectively. These doses in mice and rats are about 2.6 and 6Â times, respectively, the MRHD on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320Â mg/day and a 60-kg patient.)</p>
<p>Mutagenicity assays did not reveal any valsartan-related effects at either the gene or chromosome level. These assays included bacterial mutagenicity tests withÂ <span class="Italics">SalmonellaÂ </span>(Ames) and <span class="Italics">E. coli</span>; a gene mutation test with Chinese hamster V79 cells; a cytogenetic test with Chinese hamster ovary cells; and a rat micronucleus test.</p>
<p>Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200Â mg/kg/day. This dose is about 6Â times the MRHD on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320Â mg/day and a 60-kg patient.)</p>
<p><span class="Bold"><span class="Italics">Hydrochlorothiazide </span></span></p>
<p>Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600Â mg/kg/day) or in male and female rats (at doses of up to approximately 100Â mg/kg/day). The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice.</p>
<p>Hydrochlorothiazide was not genotoxic <span class="Italics">in vitro</span> in the Ames mutagenicity assay of <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> Typhimurium <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA 98, TA 100, TA 1535, TA 1537, and TA 1538 and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations, or <span class="Italics">in vivo</span> in assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the Drosophila sex-linked recessive lethal trait gene. Positive test results were obtained only in the <span class="Italics">in vitro</span> CHO Sister Chromatid Exchange (clastogenicity) and in the Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide from 43 to 1300Â mcgm/mL, and in the Aspergillus Nidulans non-disjunction assay at an unspecified concentration.</p>
<p>Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4Â mg/kg, respectively, prior to mating and throughout gestation.Â These doses of hydrochlorothiazide in mice and rats represent 19 and 1.5Â times, respectively, the MRHD on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 25Â mg/day and a 60-kg patient.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5a158737-1217-841d-653b-44e1c1a509a1"></a><a name="section-12.2"></a><p></p>
<h2>13.3Â Developmental Toxicity StudiesÂ </h2>
<p class="First"><span class="Bold"><span class="Italics">Valsartan-Hydrochlorothiazide </span></span></p>
<p>There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in mice, rats, or rabbits treated orally with valsartan at doses up to 600, 100 and 10Â mg/kg/day, respectively, in combination with hydrochlorothiazide at doses up to 188, 31 and 3Â mg/kg/day. These non-teratogenic doses in mice, rats and rabbits, respectively, represent 9, 3.5 and 0.5 times the MRHD of valsartan and 38, 13 and 2 times the MRHD of hydrochlorothiazide on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320Â mg/day valsartan in combination with 25Â mg/day hydrochlorothiazide and a 60-kg patient.)</p>
<p>Fetotoxicity was observed in association with maternal toxicity in rats and rabbits at valsartan doses of â‰¥200 and 10 mg/kg/day, respectively, in combination with hydrochlorothiazide doses of â‰¥63 and 3 mg/kg/day. Fetotoxicity in rats was considered to be related to decreased fetal weights and included fetal variations of sternebrae, vertebrae, ribs and/or renal papillae. Fetotoxicity in rabbits included increased numbers of late resorptions with resultant increases in total resorptions, postimplantation losses and decreased number of live fetuses. The no observed adverse effect doses in mice, rats and rabbits for valsartan were 600, 100 and 3 mg/kg/day, respectively, in combination with hydrochlorothiazide doses of 188, 31 and 1 mg/kg/day. These no adverse effect doses in mice, rats and rabbits, respectively, represent 9, 3 and 0.18 times the MRHD of valsartan and 38, 13 and 0.5 times the MRHD of hydrochlorothiazide on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient.)</p>
<p><span class="Bold"><span class="Italics">Valsartan </span></span></p>
<p>No teratogenic effects were observed when valsartan was administered to pregnant mice and rats at oral doses up to 600 mg/kg/day and to pregnant rabbits at oral doses up to 10 mg/kg/day. However, significant decreases in fetal weight, pup birth weight, pup survival rate, and slight delays in developmental milestones were observed in studies in which parental rats were treated with valsartan at oral, maternally toxic (reduction in body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and food consumption) doses of 600 mg/kg/day during organogenesis or late gestation and lactation. In rabbits, fetotoxicity (i.e., resorptions, litter loss, abortions, and low body weight) associated with maternal toxicity (mortality) was observed at doses of 5 and 10 mg/kg/day. The no observed adverse effect doses of 600, 200 and 2 mg/kg/day in mice, rats and rabbits represent 9, 6 and 0.1 times, respectively, theÂ MRHD on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)Â </p>
<p><span class="Bold"><span class="Italics">Hydrochlorothiazide </span></span></p>
<p>Under the auspices of the National Toxicology Program, pregnant mice and rats that received hydrochlorothiazide via gavage at doses up to 3000 and 1000 mg/kg/day, respectively, on gestation days 6 through 15 showed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. These doses of hydrochlorothiazide in mice and rats represent 608 and 405 times, respectively, the MRHD on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 25 mg/day and a 60-kg patient.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="_4b268e18-fa31-d730-95d0-45ed9f64cf29"></a><a name="section-13"></a><p></p>
<h1>14Â Â CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_050434b6-ae92-0317-47b5-7af08eb657aa"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First"><span class="Bold"><span class="Italics">Valsartan-Hydrochlorothiazide</span></span></p>
<p>In controlled clinical trials including over 7600 patients, 4372 patients were exposed to valsartan (80, 160, and 320 mg) and concomitant hydrochlorothiazide (12.5 and 25 mg). Two factorial trials compared various combinations of 80/12.5 mg, 80/25 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg, and 320/25 mg with their respective components and placebo. The combination of valsartan and hydrochlorothiazide resulted in additive placebo-adjusted decreases in systolic and diastolic blood pressure at trough of 14 to 21/8 to 11 mmHg at 80/12.5 mg to 320/25 mg, compared to 7 to 10/4 to 5 mmHg for valsartan 80 mg to 320 mg, and 5 to 11/2 to 5 mmHg for hydrochlorothiazide 12.5 mg to 25 mg alone.</p>
<p>Three other controlled trials investigated the addition of hydrochlorothiazide to patients who did not respond adequately to valsartan 80Â mg to valsartan 320Â mg, resulted in the additional lowering of systolic and diastolic blood pressure by approximately 4 to 12/2 to 5Â mmHg.</p>
<p>The maximal antihypertensive effect was attained 4 weeks after the initiation of therapy, the first time point at which blood pressure was measured in these trials.</p>
<p>In long-term follow-up studies (without placebo control) the effect of the combination of valsartan and hydrochlorothiazide appeared to be maintained for up to 2 years. The antihypertensive effect is independent of age or gender. The overall response to the combination was similar for black and non-black patients.</p>
<p>There was essentially no change in heart rate in patients treated with the combination of valsartan and hydrochlorothiazide in controlled trials. There are no trials of the valsartan and hydrochlorothiazide combination tablet demonstrating reductions in cardiovascular risk in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, but the hydrochlorothiazide component and several ARBs, which are the same pharmacological class as the valsartan component, have demonstrated such benefits.</p>
<p><span class="Bold"><span class="Italics">Valsartan </span></span></p>
<p>The antihypertensive effects of valsartan were demonstrated principally in 7Â placebo-controlled, 4- to 12-week trials (1 in patients over 65) of dosages from 10 to 320Â mg/day in patients with baseline diastolic blood pressures of 95 to 115. The studies allowed comparison of once-daily and twice-daily regimens of 160Â mg/day; comparison of peak and trough effects; comparison (in pooled data) of response by gender, age, and race; and evaluation of incremental effects of hydrochlorothiazide.</p>
<p>Administration of valsartan to patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> results in a significant reduction of sitting, supine, and standing systolic and diastolic blood pressure, usually with little or no orthostatic change.</p>
<p>In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs at approximately 2 hours, and maximum reduction of blood pressure is achieved within 6 hours. The antihypertensive effect persists for 24 hours after dosing, but there is a decrease from peak effect at lower doses (40 mg) presumably reflecting loss of inhibition of angiotensin II. At higher doses, however (160 mg), there is little difference in peak and trough effect. During repeated dosing, the reduction in blood pressure with any dose is substantially present within 2 weeks, and maximal reduction is generally attained after 4 weeks. In long-term follow-up studies (without placebo control) the effect of valsartan appeared to be maintained for up to 2 years. The antihypertensive effect is independent of age, gender or race. The latter finding regarding race is based on pooled data and should be viewed with caution, because antihypertensive drugs that affect the renin-angiotensin system (that is, ACE inhibitors and angiotensin II blockers) have generally been found to be less effective in low-renin hypertensives (frequently blacks) than in high-renin hypertensives (frequently whites). In pooled, randomized, controlled trials of valsartan that included a total of 140 blacks and 830 whites, valsartan and an ACE inhibitor control were generally at least as effective in blacks as whites. The explanation for this difference from previous findings is unclear.</p>
<p>Abrupt withdrawal of valsartan has not been associated with a rapid increase in blood pressure.</p>
<p>The 7 studies of valsartan monotherapy included over 2000 patients randomized to various doses of valsartan and about 800 patients randomized to placebo. Doses below 80Â mg were not consistently distinguished from those of placebo at trough, but doses of 80, 160 and 320Â mg produced dose-related decreases in systolic and diastolic blood pressure, with the difference from placebo of approximately 6 to 9/3 to 5Â mmHg at 80 to 160Â mg and 9/6Â mmHg at 320Â mg.</p>
<p>Patients with an inadequate response to 80Â mg once daily were titrated to either 160Â mg once daily or 80Â mg twice daily, which resulted in a comparable response in both groups.</p>
<p>In another 4-week study, 1876 patients randomized to valsartan 320Â mg once daily had an incremental blood pressure reduction 3/1Â mmHg lower than did 1900 patients randomized to valsartan 160Â mg once daily.</p>
<p>In controlled trials, the antihypertensive effect of once daily valsartan 80Â mg was similar to that of once daily enalapril 20Â mg or once daily lisinopril 10Â mg.</p>
<p>There was essentially no change in heart rate in valsartan-treated patients in controlled trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_b63f0241-f1e9-e4f1-cc83-83dcc159d8d0"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Initial TherapyÂ -Â <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">The safety and efficacy of valsartan and hydrochlorothiazide tablets as initial therapy for patients with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (defined as a sitting diastolic blood pressure â‰¥110Â mmHg and systolic blood pressure â‰¥140Â mmHg off all antihypertensive therapy) was studied in a 6-week multicenter, randomized, double-blind study. Patients were randomized to either valsartan and hydrochlorothiazide tablets (160/12.5Â mg once daily) or to valsartan (160Â mg once daily) and followed for blood pressure response. Patients were force-titrated at 2-week intervals. Patients on combination therapy were subsequently titrated to 160/25Â mg followed by 320/25Â mg valsartan/hydrochlorothiazide. Patients on monotherapy were subsequently titrated to 320Â mg valsartan followed by a titration to 320Â mg valsartan to maintain the blind. </p>
<p>The study randomized 608 patients, including 261 (43%) females, 147 (24%) blacks, and 75 (12%) â‰¥65 years of age. The mean blood pressure at baseline for the total population was 168/112Â mmHg. The mean age was 52 years. After 4 weeks of therapy, reductions in systolic and diastolic blood pressure were 9/5Â mmHg greater in the group treated with valsartan and hydrochlorothiazide tablets compared to valsartan. Similar trends were seen when the patients were grouped according to gender, race or age.Â </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="_fef40a03-fc38-375f-2870-e57bfeeaee09"></a><a name="section-14"></a><p></p>
<h1>16Â Â HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Valsartan and hydrochlorothiazide tablets, USP are available as tablets containing valsartan/hydrochlorothiazide 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg and 320/25 mg. All strengths are packaged in bottles as described below.</p>
<p><span class="Bold">80/12.5 mg Tablet</span> - Orange, modified capsule shaped, film-coated tablets, engraved â€œAPOâ€? on one side and â€œ80/12.5â€? on the other side.</p>
<p>Bottles of 30â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦ NDC 63187-241-30Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  </p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [See USP Controlled Room Temperature]. Protect from moisture.Â </p>
<p>Dispense in tight container (USP).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="_feeb47e2-35ac-b581-57ac-d8b7eabae16a"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Bold">Information for Patients</span></p>
<p><span class="Bold"><span class="Italics">Pregnancy </span></span></p>
<p>Female patients of childbearing age should be told about the consequences of exposure to valsartan and hydrochlorothiazide tablets during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.</p>
<p><span class="Bold"><span class="Italics">Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> </span></span></p>
<p>A patient receiving valsartan and hydrochlorothiazide tablets should be cautioned that <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> can occur, especially during the first days of therapy, and that it should be reported to the prescribing physician. The patients should be told that if <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occurs, valsartan and hydrochlorothiazide tablets should be discontinued until the physician has been consulted.</p>
<p>All patients should be cautioned that inadequate fluid intake, excessive perspiration, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> can lead to an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>, with the same consequences of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> and possible <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Bold"><span class="Italics">Potassium Supplements</span></span></p>
<p>A patient receiving valsartan and hydrochlorothiazide tablets should be told not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician.</p>
<p><br><span class="Bold">APOTEX CORP. </span></p>
<p><span class="Bold">VALSARTAN and HYDROCHLOROTHIAZIDE Tablets, USP </span></p>
<p><span class="Bold">80/12.5 mg</span></p>
<p><br><span class="Bold">Manufactured by Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Manufactured for	Repackaged by:</span></p>
<p>Apotex Research Pvt. Ltd.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Apotex Corp.	Proficient Rx LP</p>
<p>Bangalore-560 099Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weston, Florida	Thousand Oaks, CA</p>
<p>IndiaÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  33326	91320</p>
<p><br>Revised: May 2014</p>
<p>Rev. 2</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="_97b7c17a-316a-5cd3-0510-9de8de3f52b0"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">FDA-Approved Patient LabelingÂ </span></p>
<p><span class="Bold">PATIENT INFORMATIONÂ </span></p>
<p><span class="Bold">VALSARTAN and HYDROCHLOROTHIAZIDE Tablets, USP</span></p>
<p>(val sar' tan and hye'' droe klor'' oh thye' azide) <span class="Bold">Â </span></p>
<p>Read the Patient Information that comes with valsartan and hydrochlorothiazide tablets before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your condition and treatment. If you have any questions about valsartan and hydrochlorothiazide tablets, ask your doctor or pharmacist.</p>
<table width="100%">
<col width="100%">
<tbody class="Headless">
<tr class="First"><td><p class="First"><span class="Bold">What is the most important information I should know about valsartan and hydrochlorothiazide tablets?Â </span></p></td></tr>
<tr class="Last"><td><p class="First">Valsartan and hydrochlorothiazide tablets can cause harm or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to an unborn baby. Talk to your doctor about other ways to lower your blood pressure if you plan to become pregnant. Â If you get pregnant while taking valsartan and hydrochlorothiazide tablets, tell your doctor right away.</p></td></tr>
</tbody>
</table>
<p><span class="Bold">What are valsartan and hydrochlorothiazide tablets?</span>Â </p>
<p>Valsartan and hydrochlorothiazide tablets contain two prescription medicines:Â </p>
<p>1. valsartan, an angiotensin receptor blocker (ARB)</p>
<p>2. hydrochlorothiazide (HCTZ), a water pill (diuretic)</p>
<p>Valsartan and hydrochlorothiazide tablets may be used to lower high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>) in adults-</p>
<dl>
<dt>1.</dt>
<dd>when one medicine to lower your high blood pressure is not enough.Â </dd>
<dt>2.</dt>
<dd>as the first medicine to lower high blood pressure if your doctor decides you are likely to need more than one medicine.</dd>
</dl>
<p>Valsartan and hydrochlorothiazide tablets have not been studied in children under 18 years of age.</p>
<p><span class="Bold">Who should not take valsartan and hydrochlorothiazide tablets?Â </span></p>
<p><span class="Bold">Do not take valsartan and hydrochlorothiazide tablets if you:</span></p>
<dl>
<dt>1.</dt>
<dd>
<span class="Bold">are allergic to any of the ingredients in valsartan and hydrochlorothiazide tablets. </span>See the end of this leaflet for a complete list of ingredients in valsartan and hydrochlorothiazide tablets.Â </dd>
<dt>2.</dt>
<dd>make less urine due to kidney problems.Â </dd>
<dt>3.</dt>
<dd>are allergic to medicines that contain sulfonamides.</dd>
</dl>
<p><span class="Bold">What should I tell my doctor before taking valsartan and hydrochlorothiazide tablets?</span></p>
<p><span class="Bold">Tell your doctor about all your medical conditions including if you:</span></p>
<dl>
<dt>1.</dt>
<dd>
<span class="Bold">are pregnant or plan to become pregnant. </span>See â€œ<span class="Bold">What is the most important information I should know about valsartan and hydrochlorothiazide tablets?</span>â€?Â </dd>
<dt>2.</dt>
<dd>
<span class="Bold">are breast-feeding. </span>Valsartan and hydrochlorothiazide passes into breast milk. You should choose either to take valsartan and hydrochlorothiazide tablets or breast-feed, but not both.Â </dd>
<dt>3.</dt>
<dd><span class="Bold">have liver problemsÂ </span></dd>
<dt>4.</dt>
<dd><span class="Bold">have kidney problemsÂ </span></dd>
<dt>5.</dt>
<dd><span class="Bold">have or had gallstonesÂ </span></dd>
<dt>6.</dt>
<dd><span class="Bold">have LupusÂ </span></dd>
<dt>7.</dt>
<dd>
<span class="Bold">have low levels of potassium </span>(with or without symptoms such as <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, abnormal heart rhythm) or magnesium in your blood Â </dd>
<dt>8.</dt>
<dd>
<span class="Bold">have high levels of calcium in your blood </span>(with or without symptoms such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, frequent urination, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>).Â </dd>
<dt>9.</dt>
<dd><span class="Bold">have high levels of uric acid in the blood.</span></dd>
<dt>10.</dt>
<dd><span class="Bold">have ever had a reaction called <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, to another blood pressure medication. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> causes <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, throat and may cause <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>.</span></dd>
</dl>
<p><span class="Bold">Tell your doctor about all the medicines you take </span>including prescription and nonprescription medicines, vitamins and herbal supplements. Some of your other medicines and valsartan and hydrochlorothiazide tablets could affect each other, causing serious side effects. Especially, tell your doctor if you take:</p>
<dl>
<dt>1.</dt>
<dd>other medicines for high blood pressure or a heart problem</dd>
<dt>2.</dt>
<dd>water pills (diuretics)</dd>
<dt>3.</dt>
<dd>potassium supplements. Your doctor may check the amount of potassium in your blood periodically.</dd>
<dt>4.</dt>
<dd>a salt substitute. Your doctor may check the amount of potassium in your blood periodically.</dd>
<dt>5.</dt>
<dd>antidiabetic medicines including insulin</dd>
<dt>6.</dt>
<dd>narcotic <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines</dd>
<dt>7.</dt>
<dd>sleeping pills</dd>
<dt>8.</dt>
<dd>lithium, a medicine used in some types of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (Eskalith<span class="Sup">Â®</span>, Lithobid<span class="Sup">Â®</span>, Lithium Carbonate, Lithium Citrate)</dd>
<dt>9.</dt>
<dd>aspirin or other medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), like ibuprofen or naproxen</dd>
<dt>10.</dt>
<dd>digoxin or other digitalis glycosides (a heart medicine) </dd>
<dt>11.</dt>
<dd>muscle relaxants (medicines used during operations) </dd>
<dt>12.</dt>
<dd>certain cancer medicines, like cyclophosphamide or methotrexate</dd>
<dt>13.</dt>
<dd>certain antibiotics (rifamycin group), a drug used to protect against <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">transplant rejection</span> (cyclosporin) or an antiretroviral drug used to treat HIV/AIDS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (ritonavir). These drugs may increase the effect of valsartan.</dd>
</dl>
<p>Ask your doctor if you are not sure if you are taking one of these medicines.Â </p>
<p>Know the medicines you take. Keep a list of your medicines with you to show to your doctor and pharmacist when a new medicine is prescribed. Talk to your doctor or pharmacist before you start taking any new medicine. Your doctor or pharmacist will know what medicines are safe to take together.</p>
<p><span class="Bold">How should I take valsartan and hydrochlorothiazide tablets?</span></p>
<dl>
<dt>1.</dt>
<dd>Take valsartan and hydrochlorothiazide tablets exactly as prescribed by your doctor. Your doctor may change your dose if needed.Â </dd>
<dt>2.</dt>
<dd>Take valsartan and hydrochlorothiazide tablets once each day.Â </dd>
<dt>3.</dt>
<dd>Valsartan and hydrochlorothiazide tablets can be taken with or without food.Â </dd>
<dt>4.</dt>
<dd>If you miss a dose, take it as soon as you remember. If it is close to your next dose, do not take the missed dose. Just take the next dose at your regular time.Â </dd>
<dt>5.</dt>
<dd>If you take too much valsartan and hydrochlorothiazide tablets, call your doctor or Poison Control Center, or go to the nearest hospital emergency room.</dd>
</dl>
<p><span class="Bold">What should I avoid while taking valsartan and hydrochlorothiazide tablets?</span></p>
<p>You should not take valsartan and hydrochlorothiazide tablets during pregnancy. See â€œWhat is the most important information I should know about valsartan and hydrochlorothiazide tablets?â€?Â </p>
<p><span class="Bold">What are the possible side effects of valsartan and hydrochlorothiazide tablets?Â </span></p>
<p><span class="Bold">Valsartan and hydrochlorothiazide tablets may cause serious side effects including:</span></p>
<dl>
<dt>1.</dt>
<dd>
<span class="Bold">Harm to an unborn baby causing injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span>See â€œ<span class="Bold">What is the most important information I should know about valsartan and hydrochlorothiazide tablets?</span>â€?Â </dd>
<dt>2.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>). </span><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> is most likely to happen if you:Lie down if you feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> or dizzy. Call your doctor right away.<dl>
<dt>â€¢</dt>
<dd>take water pills</dd>
<dt>â€¢</dt>
<dd>are on a low salt diet</dd>
<dt>â€¢</dt>
<dd>get dialysis treatments</dd>
<dt>â€¢</dt>
<dd>have heart problems</dd>
<dt>â€¢</dt>
<dd>get sick with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>â€¢</dt>
<dd>drink alcohol</dd>
</dl>
</dd>
<dt>3.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>. </span>People with and without <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> problems or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> who take valsartan and hydrochlorothiazide tablets may get <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.Â </dd>
<dt>4.</dt>
<dd>
<span class="Bold">Worsening of Lupus. </span>Hydrochlorothiazide, one of the medicines in valsartan and hydrochlorothiazide tablets may cause Lupus to become active or worse.Â </dd>
<dt>5.</dt>
<dd>
<span class="Bold">Fluid and electrolyte (salt) problems. </span>Tell your doctor about any of the following signs and symptoms of fluid and electrolyte problems:</dd>
</dl>
<table width="100%">
<col width="33%">
<col width="34%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">â—? <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></p></td>
<td><p class="First">â—? <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></p></td>
<td><p class="First">â—?<span class="product-label-link" type="condition" conceptid="4214612" conceptname="Muscle fatigue">muscle fatigue</span></p></td>
</tr>
<tr>
<td><p class="First">â—? <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span></p></td>
<td><p class="First">â—? <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></p></td>
<td><p class="First">â—? very low urine output</p></td>
</tr>
<tr>
<td><p class="First"> â—? lack of energy (<span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargic</span>)</p></td>
<td><p class="First">â—? <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></p></td>
<td><p class="First">â—? fast heartbeat</p></td>
</tr>
<tr>
<td><p class="First">â—? <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></p></td>
<td><p class="First">â—? <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></p></td>
<td><p class="First">â—? <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p></td>
</tr>
<tr class="Last">
<td></td>
<td><p class="First">â—? <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span></p></td>
<td></td>
</tr>
</tbody>
</table>
<dl>
<dt>1.</dt>
<dd>
<span class="Bold">Kidney problems. </span>Kidney problems may become worse in people that already have kidney disease. Some people will have changes on blood tests for kidney function and may need a lower dose of valsartan and hydrochlorothiazide tablets. Call your doctor if you get <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your feet, ankles, or hands, or unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. If you have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, your doctor should check your kidney function before prescribing valsartan and hydrochlorothiazide tablets.<span class="Bold">Â </span>
</dd>
<dt>2.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span>. </span>Call your doctor right away if you have an unusual <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>.Â </dd>
<dt>3.</dt>
<dd>
<span class="Bold">Eye Problems. </span>One of the medicines in valsartan and hydrochlorothiazide tablets can cause eye problems that may lead to <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>. Symptoms of eye problems can happen within hours to weeks of starting valsartan and hydrochlorothiazide tablets. Tell your doctor right away if you have:<dl>
<dt>1.</dt>
<dd>decrease in vision </dd>
<dt>2.</dt>
<dd><span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span></dd>
</dl>
</dd>
</dl>
<p>Other side effects were generally mild and brief. They generally have not caused patients to stop taking valsartan and hydrochlorothiazide tablets.Â </p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.Â </p>
<p>These are not all the possible side effects of valsartan and hydrochlorothiazide tablets. For a complete list, ask your doctor or pharmacist.Â </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.<span class="Bold">Â </span></p>
<p><span class="Bold">How do I store valsartan and hydrochlorothiazide tablets?</span></p>
<dl>
<dt>1.</dt>
<dd>Store valsartan and hydrochlorothiazide tablets at room temperature between 59Â°F to 86Â°F (15Â°C to 30Â°C).</dd>
<dt>2.</dt>
<dd>Keep valsartan and hydrochlorothiazide tablets in a closed container in a dry place.</dd>
</dl>
<p><span class="Bold">Keep valsartan and hydrochlorothiazide tablets and all medicines out of the reach of children.Â </span></p>
<p><span class="Bold">General information about valsartan and hydrochlorothiazide tablets</span>Â </p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use valsartan and hydrochlorothiazide tablets for a condition for which it was not prescribed. Do not give valsartan and hydrochlorothiazide tablets to other people, even if they have the same symptoms you have. It may harm them.Â </p>
<p>This leaflet summarizes the most important information about valsartan and hydrochlorothiazide tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about valsartan and hydrochlorothiazide tablets that is written for health professionals. For more information about valsartan and hydrochlorothiazide tablets, call Apotex Corp. at 1-800-706-5575.</p>
<p><span class="Bold">What are the ingredients in valsartan and hydrochlorothiazide tablets?</span>Â </p>
<p>Active ingredients: Valsartan and hydrochlorothiazideÂ </p>
<p>Inactive ingredients: dibasic calcium phosphate dihydrate, powdered cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate (vegetable source), hydroxypropyl methylcellulose, hydroxypropyl cellulose, titanium dioxide, yellow iron oxide (80/12.5 mg, 160/25 mg and 320/25 mg), euroxide red iron oxide (80/12.5 mg, 160/12.5 mg, 160/25 mg and 320/12.5 mg) and black iron oxide (160/25 mg and 320/12.5 mg)<span class="Bold">Â </span></p>
<p><span class="Bold">What is high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>)?</span>Â </p>
<p>Blood pressure is the force in your blood vessels when your heart beats and when your heart rests. You have high blood pressure when the force is too much. Valsartan and hydrochlorothiazide tablets can help your blood vessels relax and reduce the amount of water in your body so your blood pressure is lower. Medicines that lower blood pressure lower your risk of having a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.Â </p>
<p>High blood pressure makes the heart work harder to pump blood throughout the body and causes damage to the blood vessels. If high blood pressure is not treated, it can lead to <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, and vision problems.</p>
<p>All registered trademarks in this document are the properties of their respective owners.</p>
<p><br><span class="Bold">APOTEX CORP. </span></p>
<p><span class="Bold">VALSARTAN and HYDROCHLOROTHIAZIDE Tablets, USP </span></p>
<p><span class="Bold">80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg, and 320/25 mg</span><br><br></p>
<p><span class="Bold">Manufactured by Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Manufactured for	Repackaged by:</span></p>
<p>Apotex Research Pvt. Ltd.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Apotex Corp.	Proficient Rx LP</p>
<p>Bangalore-560 099Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weston, Florida	Thousand Oaks, CA</p>
<p>IndiaÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  33326	91320</p>
<p><br>Revised: May 2014</p>
<p>Rev. 2</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_b5f4208e-915e-265c-8855-9efc405f4aa5"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label â€“ 80 mg/12.5 mg</span></p>
<p>Rx Only Â Â Â Â Â  Â Â Â Â Â  NDC 63187-241-30</p>
<p>valsartan and hydrochlorothiazide, USPÂ </p>
<p>80 mg/12.5 mg</p>
<p>30 tablets</p>
<p>Dosage: See package insert</p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [See USP Controlled Room Temperature]. </p>
<p>Protect from moisture.</p>
<p>Dispense in tight container (USP).</p>
<p>Please see accompanying full Prescribing Information.</p>
<div class="Figure">
<a name="id2382"></a><img alt="Valsartan 80mg/Hetz 12.5mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6b6ad6c8-22f8-456b-bc54-a02fb6cbea8c&amp;name=80-12-5-90-bottle-label.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VALSARTAN AND HYDROCHLOROTHIAZIDEÂ 		
					</strong><br><span class="contentTableReg">valsartan and hydrochlorothiazide tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63187-241(NDC:60505-3806)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VALSARTAN</strong> (VALSARTAN) </td>
<td class="formItem">VALSARTAN</td>
<td class="formItem">80Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">12.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POWDERED CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (15000 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (Light orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">APO;80;12;5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63187-241-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA203026</td>
<td class="formItem">03/21/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Proficient Rx LP
							(079196022)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Proficient Rx LP</td>
<td class="formItem"></td>
<td class="formItem">079196022</td>
<td class="formItem">RELABEL(63187-241), REPACK(63187-241)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6b6ad6c8-22f8-456b-bc54-a02fb6cbea8c</div>
<div>Set id: 6b6ad6c8-22f8-456b-bc54-a02fb6cbea8c</div>
<div>Version: 1</div>
<div>Effective Time: 20140901</div>
</div>
</div>Â <div class="DistributorName">Proficient Rx LP</div></p>
</body></html>
